When the genetic material responsible for stimulating immune responses is cloned into genetically engineered microorganisms, including viruses, bacteria and protozoa, these microorganisms can be called vectors. Application of vector material induces a wide range of immune responses while enhancing heterologous antigen-specific immunity. Recombinant vectored veterinary vaccine use combines the advantages of live vaccines with those of subunit vaccines. BioVenic specializes in a variety of vaccine technologies, including recombinant vector vaccines, to provide you with multiple types of vector platforms to help you realize the development of recombinant vectored veterinary vaccines.
Vector Development Services
Virus Vector Development
Recombinant vectors play a key factor in the development of novel vaccines. Several viruses such as poxviruses, adenoviruses, mini-viruses, flaviviruses, metaviruses and herpesviruses have been utilized in viral vector vaccine development. We provide a one-stop solution from gene synthesis to virus packaging to meet your needs for recombinant virus vectored veterinary vaccine. Here are some virus vector platforms BioVenic offers for you.
|
Types of Virus Vector
|
Advantages
|
Limitations
|
|
Lentivirus
|
-
Large packaging capacity.
-
Integrating ability.
-
Transducing non-dividing cells.
-
Ability to be pseudotyped.
|
-
Concerns over insertional mutagenesis.
|
|
Poxvirus
|
-
Large packaging capacity.
-
Ability to induce a strong cellular immune response.
-
Broad host range.
|
-
Inability to induce strong immune responses in clinical trials.
|
|
Herpesvirus
|
-
Large packaging capacity.
-
Capable of superinfecting a host.
-
Induces a long-lived T-cell response.
-
Ease of manipulation.
|
-
Causes lifelong infections in hosts so needs to be attenuated.
|
|
Adenovirus
|
-
Broad tropism.
-
Variety of systems developed and tested.
-
Strong gene expression.
|
-
Preexisting immunity to adenoviral species like Ad5.
-
Possible side effects.
|
|
Adeno-associated virus (AAV)
|
-
Safe.
-
Wide host range.
-
Good spreadability.
-
Stable expression over a long period.
|
|
The diagram below illustrates BioVenic's viral packaging service process.
Bacterial Vector Development
Bacterial live vector vaccine is a new type of vaccine, after immunization, it can express a large number of exogenous genes and stimulate the body to produce cellular immunity, humoral immunity and mucosal immunity. Some of its lipid components can also play the role of adjuvant, and oral vaccines are easy to inoculate, with low cost.
|
Types of Bacterial Vector
|
Advantages
|
Limitations
|
|
Lactobacillus spp.
|
-
Non-pathogenic bacteria.
-
Non-colonizing bacteria.
-
Easy to manipulate.
|
-
Unable to induce the cellular immune response.
|
|
Salmonella spp.
|
-
Able to induce both cellular and humoral immune responses.
-
Well-established protocol for genetic manipulation.
|
-
Possible reversion to pathogenic wild-type.
|
|
Listeria monocytogenes
|
-
Able to induce both cellular and humoral immune responses.
|
-
Highly pathogenic.
-
Possible reversion to a pathogenic state.
|
Selection of genes to knock-out for the attenuation of bacterial vectors is required for the development of strong vaccine systems. BioVenic provides attenuation services, including radiation mutation, to help you meet the balance between maximal immunogenicity towards minimal side-effects. There are two main ways to construct recombinant bacterial live vector vaccines.
-
Insertion of exogenous genes into bacterial chromosomes.
-
Insertion of exogenous genes into bacterial plasmids.
BioVenic provides plasmids construction service and plenty of recombinant technology platforms, including homologous recombination technology, bacterial artificial chromosome technology, and CRISPR-Cas9 system.
Fig.2 Use of bacterial vector vaccines against pathogens.2
Protozoan Vector Development
As a pathogen with high immunogenicity, Eimeria parasites stimulate broad immunity, while its relatively large genome provides a relatively large capacity to carry heterologous antigenic genes, and Eimeria-based vector vaccines do not reduce their immunogenicity when vaccinated by oral administration. BioVenic provides clean and reliable host animals for the production of Eimeria parasites as vectors, as well as gene editing technologies such as CRISPR-Cas9 system to reduce its pathogenicity.
Fig.3 The program of recombinant Eimeria production and the use of Eimeria vectors to vaccinate against heterologous pathogens.3
In the development of recombinant vectored veterinary vaccines, the use of viruses, bacteria and protozoa as vectors for antigenic sequences requires stringent quality control. Company offers a full range of quality control services for your development process.
-
Virus Titer Assay
-
Residual Host Cell DNA
-
Residual Plasmids
-
Bacteria
-
Mycoplasma
-
Endotoxin Assay
Recombinant Vectored Veterinary Vaccine Development Services
Regardless of the type of vector, it is biologically active, and while it is easier to stimulate the immune system of vaccinated animals, safety is also a concern. BioVenic provides in vitro and in vivo safety and immunogenicity assessments to help you understand all aspects of recombinant vectored veterinary vaccines under development.
BioVenic also provides vaccine formulation development strategies to improve the stability of active ingredients in vaccines and increase the immunization success rate of vaccinated animals by rationally modifying auxiliary components of vaccines.
Our Advantages
Integrated Services
Company provides integrated services from gene synthesis for recombinant virus vector production.
Multiple Vector Choices
Company offers a wide range of vectors for veterinary vaccine development.
Efficient and On-time
Strict quality control and mature project management help to shorten the delivery time.
BioVenic is committed to excellence and is your first choice for the development of recombinant vectored veterinary vaccines for livestock, poultry, companion animals, aquaculture species and more. We provide you with customized solutions that ensure the highest levels of safety, immunogenicity and efficacy. From vector design to comprehensive quality control, our partnership with you paves the way for innovative veterinary vaccine solutions. Contact us now and make us your trusted ally!
References
-
Vrba, Sophia M., et al. "Development and applications of viral vectored vaccines to combat zoonotic and emerging public health threats." Vaccines 8.4 (2020): 680.
-
Lin, I. Y.; et al. "Live-attenuated bacterial vectors: tools for vaccine and therapeutic agent delivery." Vaccines 3.4 (2015): 940-972.
-
Tang, X.; et al. "Towards innovative design and application of recombinant eimeria as a vaccine vector." Infection and Immunity 88.5 (2020): 10-1128.
